Related Experiment Video

Updated: Apr 29, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.4K

Evolution of androgen receptor targeted therapy for advanced prostate cancer

Yien Ning Sophia Wong1, Roberta Ferraldeschi2, Gerhardt Attard3

  • 1Prostate Targeted Therapy Group, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, 15 Cotswold Road, Sutton, London SM2 5NG, UK.

Nature Reviews. Clinical Oncology
|May 21, 2014
PubMed

Insights

Prostate cancer treatment relies on androgen depletion, but resistance is common. Newer androgen receptor therapies offer hope, with ongoing research addressing future challenges in advanced prostate cancer.

Area of Science:

  • Oncology
  • Urology
  • Pharmacology

Background:

  • Androgen dependence is fundamental to prostate cancer treatment since 1941.
  • Most patients develop castration-resistant prostate cancer after initial androgen depletion therapy response.

Purpose of the Study:

  • To review the historical development of androgen receptor (AR) targeting agents.
  • To discuss current and future challenges in advanced prostate cancer therapeutics.

Main Methods:

  • Literature review of androgen receptor targeting agents.
  • Analysis of mechanisms driving resistance to castration.
  • Discussion of next-generation AR-targeting drugs like abiraterone acetate and enzalutamide.

Main Results:

  • Androgen depletion therapy (ADT) is a cornerstone but leads to inevitable resistance.
  • Understanding resistance mechanisms has spurred development of novel AR-targeting agents.
  • Abiraterone acetate and enzalutamide represent significant advancements in managing advanced prostate cancer.

Conclusions:

  • The evolution of AR-targeting agents has transformed advanced prostate cancer treatment.
  • Continued research is crucial to overcome resistance and improve patient outcomes.
  • Future strategies must address the complexities of castration-resistant prostate cancer.

More Related Videos

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

1.1K
Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

5.8K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.4K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K